Overactive Bladder Clinical Trial
Official title:
'The Experience Sampling Method (ESM): a Real-time Patient-Reported Outcome Measure for Symptom Assessment in Patients With Overactive Bladder Syndrome.'
Rationale: The overactive bladder syndrome is diagnosed clinically by using the ICS criteria
of ≥8 micturitions and at least 1 urgency episode per 24 hours. To determine whether patients
fit the criteria, micturition diaries ('sensation-related bladder diaries') and other symptom
questionnaires with considerable limitations are used. This makes it difficult to get a good
impression of the fluctuation of complaints during the day / week. These limitations are
overcome using the Experience Sampling Method (ESM). This is an electronic questioning method
which is characterized by repeated and random, momentary assessments in the subject's current
environment and state. This study follows other successful ESM studies done within the
Gastroenterology and Psychiatry Department. The aim of this study is to evaluate if the ESM
is more accurate in the assessment of urological complaints in OAB compared to the current
assessment with the use of the sensations-related bladder diaries (SR-BDs) and retrospective
questionnaires. Furthermore the aim is to assess the reliability and validity of this
OAB-specific electronic patient-reported outcome measure (ePRO), based on the Experience
Sampling Method-principle, for symptom assessment and assessment of triggers for symptoms in
OAB.
Objective: To evaluate the accuracy of the ESM to assess urological complaints in OAB
compared to SR-BDs and retrospective questionnaires. To assess content validity, reliability
and the accuracy to validate the developed ePRO in OAB patients.
Study design: The ESM study is a multicentre, prospective, cross-sectional study.
Study population: 66 OAB patients will be recruited at the outpatient Pelvic Care Centre in
Maastricht UMC+, Zuyderland Hospital and University Hospital Antwerp, 66 healthy volunteers
will be recruited as well.
Methods: In a period of 7 days, participants will fill out an electronic ESM assessment at 10
random moments during the day. Moreover, they will fill out a sensation-related bladder diary
(SR-BD) during the last three consecutive days of filling out the ESM and several symptom
questionnaires at the end of the study period.
Main study endpoints: The main study outcome comprehends the psychometric properties of the
PROM for symptom assessment of OAB symptoms. Secondary outcomes are increase in ESM score for
OAB symptoms and environmental and psychosocial factors (e.g. as measured by the PROM) from
one time point (t-1) to the next (t).
The overactive bladder syndrome (OAB) is defined by the International Continence Society
(ICS) as a symptom complex of urgency, usually with frequency and nocturia (awakening at
night to void), with (OAB wet) or without (OAB dry) urinary urgency incontinence. Urgency is
the complaint of a sudden compelling desire to pass urine, which is difficult to defer. OAB
is clinically diagnosed using the ICS criteria of ≥8 micturitions and at least 1 urgency
episode per 24 hours.
It is estimated that approximately 16-17% of the adult population of the Western world is
affected by OAB. The incidence of OAB, both wet and dry increases by age, and because of the
worldwide ageing of the population, the number of adults affected by urinary urgency
incontinence (UUI) would increase. The health care costs of OAB are high, and work
productivity can be significantly impacted as well. In addition, OAB can be associated with
comorbidity and increased mortality. Furthermore, OAB with and without incontinence has been
associated with significantly lower quality of life scores compared to matched controls
without voiding complaints. It is of particular interest that OAB does not only affect the
patients, but also has an impact on family members.
There is a strong association between OAB and psychiatric comorbidities such as depression,
anxiety and stress. This association is most likely bidirectional.
The current methods of diagnosis rely on voiding diaries (the sensation-related bladder
diary) and retrospective questionnaires.
Retrospective, self-reported outcomes have important limitations. Firstly, there is a high
risk for recall bias, in which retrospective information consists of a reconstruction of a
few specific moments rather than a reliable reflection of symptoms over a predefined period
of time. Furthermore, it is well described that memory retrieval is influenced by the
individual's environment and mental state at the time of recall, known as ecological bias. In
conclusion, patient experiences about symptoms in the past can be significantly distorted
when retrospectively reported. Furthermore, lack of patient compliance is an important
disturbing factor in recalled assessments. Studies that employed paper diaries in a
population of patients with chronic somatic pain to measure symptoms resulted in very low
patient compliance: only 11% actual compliance, but up to 80% fake compliance was determined,
the latter presumably resulting from filling in diaries after the proscribed time window.
The Experience Sampling Method (ESM), also referred to as Ecological Momentary Assessment
(EMA), may overcome these limitations. ESM is an electronic questioning method characterized
by random, repeated assessments in the subject's current state and environment, for several
consecutive days. A digital device sends out an auditory beep at random moments during the
day, to which subjects have to respond by completing several assessments at the device. The
assessments are identical between the moments. Hereby, ESM offers the opportunity to reduce
the risk for recall bias and to capture symptom variability over time with taking into
account contextual, social and psychological factors, which might have an impact on symptom
reporting.
ESM has already been used in different patient populations with different disorders, such as;
irritable bowel syndrome (IBS), depression, Parkinson's Disease and mental illness in a broad
sense.
ESM has proven to be a viable and novel approach to assess symptoms, affective states and
contextual factors at the level of the individual subject. It provides precise, prospective
information that may contribute to clinical practice with several distinct advantages over
traditionally used (retrospective) assessment of mental health related phenomena. OAB shows
fluctuating symptom patterns in which urological complaints might be influenced by daily life
factors as well as psychological and psychiatric comorbidities. To our knowledge, there are
no previous studies on the use of ESM in a urological patient population. In order to study
the performance of ESM in a population as such there is a need for developing a
patient-reported outcome measure suitable for real-time symptom assessment of urological
symptoms, using the ESM principle. Patient-reported outcome measures (PROMs) are assessment
methods completed by patients, and are meant to capture one or several aspects of a disease
course or health status. Focus group research in OAB patients was done for item selection and
to evaluate the quality of the PROMs according to the ESM principle. The outcomes of the
focus groups have been discussed in an expert meeting and a final questionnaire has been
constructed, specifically for the ESM in the urological patient population. Now, this
OAB-specific ESM tool should be tested to see if there is a difference between symptom scores
on ESM and the currently used retrospective reports and SR-BDs. Furthermore content validity,
reliability and the accuracy will be tested to validate the developed ePRO in OAB patients.
Additionally, specific triggers for the onset of OAB complaints will be objectified, with use
of the OAB specific ESM tool. It will be objectified if there is a direct link between OAB
and psychiatric disorders as depression, anxiety and stress too.
Summarizing, electronic, repeated symptom assessments during daily activities should assure
ecological validity and eliminate recall bias, lead to higher compliance rates, and capture
symptom variability during the day. For these reasons it is expected that the Experience
Sampling Method (ESM) may prove to be a more objective tool for evaluation and quantification
of urgency and other urological complaints that will overcome the limitations of currently
used retrospective symptom assessment methods in OAB.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Completed |
NCT00910845 -
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
|
Phase 3 |